El rol de las citoquinas | 11 AGO 14

La relación entre depresión e inflamación

La naciente consciencia del interjuego entre el estrés, la inflamación y la depresión puede ampliar el enfoque terapéutico.
Autor/a: Dr. Almond Maria Current Psychiatry 2013;12:25-32
INDICE:  1.  | 2. Referencias

1. Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depresión: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
2. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123-137.
3. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depresión. Trends Immunol. 2006;27(1):24-31.
4. Lamers F, Vogelzangs N, Merikangas KR, et al. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depresión [published online October 23, 2012]. Mol Psychiatry. doi: 10.1038/mp.2012.144.
5. Hoen P, Kupper N, de Jonge P. Depression and cardiovascular disease progression: epidemiology, mechanisms and treatment. In: Hjemdahl P, Rosengren A, Steptoe A, eds. Stress and cardiovascular disease. London, United Kingdom: Springer; 2012:211-233.
6. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depresión in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069-1078.
7. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61(6):822-829.
8. Dickens C, McGowan L, Clark-Carter D, et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002;64(1):52-60.
9. Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmunity and infections as risk factors for depresión and other severe mental illnesses. Neurology, Psychiatry and Brain Research. 2012;18(2):40-41.
10. National Cancer Institute. Depression (PDQ). http://www.cancer.gov/cancertopics/pdq/supportivecare/ depresión/HealthProfessional/page1. Updated January 9, 2013. Accessed April 23, 2013.
11. Centers for Disease Control and Prevention. Current depresión among adults—United States, 2006 and 2008. Morb Mortal Wkly Rep. 2010;59(38):1229-1235.
12. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83(5):495-502.
13. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of citocinas in the pathophysiology of major depresión. Biol Psychiatry. 2009;65(9):732-741.
14. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of citocinas in major depresión. Biol Psychiatry. 2010;67(5):446-457.
15. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depresión and treatment resistant depresión. Cytokine. 1997;9(11):853-858.
16. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66(1):41-48.
17. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depresión during interferon-alpha therapy. Am J Psychiatry. 2003;160(7): 1342-1345.
18. Eisenberger NI, Berkman ET, Inagaki TK, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68(8):748-754.
19. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depresión. Br J Psychiatry. 2010;197(5):372-377.
20. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depresión: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41.
21. Martinez JM, Garakani A, Yehuda R, et al. Proinflammatory and “resiliency” proteins in the CSF of patients with major depresión. Depress Anxiety. 2012;29(1):32-38.
22. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370-379.
23. Raison CL, Miller AH. Is depresión an inflammatory disorder? Curr Psychiatry Rep. 2011;13(6):467-775.
24. Maes M, Song C, Lin A, et al. The effects of psychological stress on humans: increased production of pro-inflammatory citocinas and Th1-like response in stress-induced anxiety. Cytokine. 1998;10(4):313-318.
25. Miller GE, Rohleder N, Stetler C, et al. Clinical depresión and regulation of the inflammatory response during acute stress. Psychosom Med. 2005;67(5):679-687.
26. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160(9):1554-1565.
27. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107(1):7-12.
28. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depresión. Mol Psychiatry. 2007;12(11):988-1000.
29. Capuron L, Fornwalt FB, Knight BT, et al. Does cytokine-induced depresión differ from idiopathic major depresión in medically healthy individuals? J Affect Disord. 2009;119(1- 3):181-185.
30. Yirmiya R, Pollak Y, Morag M, et al. Illness, citocinas, and depresión. Ann N Y Acad Sci. 2000;917(1):478-487.
31. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol. 2001;16(1):95-103.
32. Szuster-Ciesielska A, Tustanowska-Stachura A, Słotwin`ska M, et al. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol. 2003;55(3):353-362.
33. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012;10(1):66.
34. Hestad KA, Tønseth S, Støen CD, et al. Raised plasma levels of tumor necrosis factor [alpha] in patients with depresión: normalization during electroconvulsive therapy. J ECT. 2003;19(4):183-188.
35. Maier SF, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 1995;695(2):279-282.
36. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22(2):101-110.
37. Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther. 2000;22(1):128-139.
38. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depresión and high inflammation. Brain, Behavior, and Immunity. 2012;26(suppl 1):S49.
39. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depresión: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680-684.
40. Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depresión using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol. 2006;21(4):227-231.
41. Brunello N, Alboni S, Capone G, et al. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depresión. Int Clin Psychopharmacol. 2006;21(4):219-225.




Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023